Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326555 | 0.89 | RXRA (0.47) | RXRAPPARGNR1H3SMN1; SMN2HCAR3 | |
| SCHEMBL17326619 | 0.87 | RXRA (0.47) | RXRAPPARGNR1H3SMN1; SMN2THRB | |
| SCHEMBL17326599 | 0.86 | RXRA (0.52) | RXRASMN1; SMN2HCAR3PTPN11THRB | |
| SCHEMBL17326601 | 0.76 | RXRA (0.50) | RXRAPTPN11 | |
| SCHEMBL17326569 | 0.75 | RXRA (0.50) | RXRAPPARGSMN1; SMN2HCAR3THRB | |
| SCHEMBL17326802 | 0.74 | RXRA (0.48) | RXRAPTPN11 | |
| SCHEMBL25484516 | 0.73 | RXRA (0.63) | RXRASMN1; SMN2PTPN11 | |
| SCHEMBL17326618 | 0.73 | RXRA (0.50) | RXRASMN1; SMN2THRB | |
| SCHEMBL22250090 | 0.71 | RXRA (0.49) | RXRAPPARGNR1H3SMN1; SMN2HCAR3 | |
| SCHEMBL22235452 | 0.70 | RXRA (0.54) | RXRAPPARGNR1H3SMN1; SMN2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015187850-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF OCULAR DISORDERS | DUKE UNIVERSITY (US) | 2015-12-10 | — | — | WO | disclosed |